EU Big Data Report Takeaways Ready ‘In Weeks’
EU regulators have been working on a project to help determine the potential role of big data in medicines assessment for almost two years. They will soon be ready to release their keenly awaited conclusions.
You may also be interested in...
EU regulators have produced the first fruits of their ambitious “big data” project aimed at ensuring that the EU drug regulatory system can make full use of the rapidly increasing volume and complexity of data being gathered across multiple settings in the healthcare area.
Changing mindsets, technologies outpacing regulatory frameworks, intense international collaboration, and the future of the randomized controlled clinical trial. Big data is forcing us to think big, senior European regulator Thomas Senderovitz tells the Pink Sheet.
EU drug regulators have created a new task force to establish a roadmap and recommendations on how to use big data in the assessment of medicines.